Vol. 18 No. 1, January - January 2014
Index
- Diagnostic patents at the Supreme Court.
- Forward-looking view of healthcare innovation, from a leading life science venture capitalist.
- The increasing importance of biologics-based drugs in pharmaceutical pipelines.
- Need for new IP approaches to facilitate collaborative (academic-industrial) drug development.
- New business models to find cures and lower healthcare costs: a role for drug repurposing.
- Repurposing & collaborative drug development for rare diseases.
- The future of clinical trials: more transparency and pharmacogenomics.
- Implications of genomics advances for drug discovery, clinical therapies, & rare disease research.
- Intellectual property rights (IPR) in collaborative drug development in the EU: helping a European public-private partnership deliver - the need for a flexible approach to IPR.
- A new framework for assessing clinical data transparency initiatives.
- A new framework for assessing clinical data transparency initiatives.
- Ancillary orders of compulsory licensing and their compatibility with the TRIPs Agreement.
- The new era of biologic regulation and patenting under the America Invents Act.
- Repurposing - finding new uses for old (and patented) drugs: bridging the "Valley of Death," to translate academic research into new medicines.
- Trademarks under the North American Free Trade Agreement (NAFTA), with references to the current Mexican law.
- Territoriality challenges in protecting trademark interests in the system of generic top-level domains (gTLDs).
- How media got the biggest bite of (the) Apple: a look at the media misperception in the Apple-Samsung case.